JP Morgan Chase’s Albany Molecular Research Inc AMRI Stock Holding History

JP Morgan Chase’s Portfolio AMRI Stock Details AMRI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q2	–	Sell	-4,798,830	Closed	-$67.3M	–	5437
2017 Q1	$67.3M	Hold	4,798,830	–	–	0.02%	792
2016 Q4	$90M	Hold	4,798,830	–	–	0.02%	629
2016 Q3	$79.2M	Hold	4,798,830	–	–	0.02%	642
2016 Q2	$64.5M	Hold	4,798,830	–	–	0.02%	730
2016 Q1	$73.4M	Buy	+4,798,830	New	+$75.2M	0.02%	654

Other funds holding AMRI

Ancora Advisors Cleveland, Ohio $4.7B AUM 19.05% 1-Year Est. Return

DekaBank Deutsche Girozentrale Frankfurt, Germany $60.6B AUM 23.27% 1-Year Est. Return

JP Morgan Chase's AMRI Position: Q3 2017 in Review

JP Morgan Chase sold out of Albany Molecular Research Inc (AMRI) in Q3 2017, closing a stake of 987,235 shares — an estimated $21.4M sold.

JP Morgan Chase first reported a position in AMRI in Q2 2013 and held it in 15 quarters. The position peaked at $21.4M in Q2 2017. 2 funds tracked by Wall St. Rank hold AMRI as of Q3 2017.

JP Morgan Chase reported no remaining Albany Molecular Research Inc position as of Q3 2017 after selling out during the quarter.
JP Morgan Chase sold 987,235 Albany Molecular Research Inc shares in Q3 2017, an estimated $21.4M.
JP Morgan Chase first reported a position in Albany Molecular Research Inc in Q2 2013 and held it in 15 quarters.
JP Morgan Chase's Albany Molecular Research Inc position peaked at $21.4M in Q2 2017.
2 funds tracked by Wall St. Rank held Albany Molecular Research Inc as of Q3 2017.

Based on JP Morgan Chase's 13F filing for Q3 2017, filed 9 Nov 2017.